Helix BioPharma's total assets for Q2 2025 were C$2.24M, an increase of 441.55% from the previous quarter. TSE:HBP total liabilities were C$2.26M for the fiscal quarter, a 27.17% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.